Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose

Lung Cancer

Volumn 79, Issue 1, 2013, Pages 8-13

  Li, Hang ^a,b   Pan, Yunjian ^a,b   Li, Yuan ^a,b   Li, Chenguang ^a,b   Wang, Rui ^a,b   Hu, Haichuan ^a,b   Zhang, Yang ^a,b   Ye, Ting ^a,b   Wang, Lei ^a,b   Shen, Lei ^a,b   Sun, Yihua ^a,b   Chen, Haiquan ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Driver mutations; Lung adenocarcinoma; Smokers

Indexed keywords

B RAF KINASE; EMLA ALK PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KRAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX; SMOKING;

ADENOCARCINOMA; ADULT; AGED; CHINA; DNA MUTATIONAL ANALYSIS; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; ONCOGENES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SMOKING;

EID: 84871095066     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.09.018     Document Type: Article

References (38)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
4. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
5. Leicht D.T., Balan V., Kaplun A., Singh-Gupta V., Kaplun L., Dobson M., et al. Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta 2007, 1773:1196-1212.
6. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
7. Toh C.K., Wong E.H., Lim W.T., Leong S.S., Fong K.W., Wee J., et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest 2004, 126:1750-1756.
8. Pfeifer G.P., Denissenko M.F., Olivier M., Tretyakova N., Hecht S.S., Hainaut P. Tobacco smoke carcinogens. DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002, 21:7435-7451.
9. Ahrendt S.A., Decker P.A., Alawi E.A., Zhu Yr Y.R., Sanchez-Cespedes M., Yang S.C., et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001, 92:1525-1530.
10. Sun Y., Ren Y., Fang Z., Li C., Fang R., Gao B., et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 2010, 28:4616-4620.
11. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003, 21:2237-2246.
12. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004, 22:1103-1109.
13. Carpenter C.L., Morgenstern H., London S.J. Alcoholic beverage consumption and lung cancer risk among residents of Los Angeles county. J Nutr 1998, 128:694-700.
14. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136:260-271.
15. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
16. Huang S.F., Liu H.P., Li L.H., Ku Y.C., Fu Y.N., Tsai H.Y., et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004, 10:8195-8203.
17. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
18. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450:893-898.
19. Motoi N., Szoke J., Riely G.J., Seshan V.E., Kris M.G., Rusch V.W., et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes. EGFR mutations and gene expression analysis. Am J Surg Pathol 2008, 32:810-827.
20. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
21. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
22. Fisher G.H., Wellen S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J., et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001, 15:3249-3262.
23. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
24. Chitale D., Gong Y., Taylor B.S., Broderick S., Brennan C., Somwar R., et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 2009, 28:2773-2783.
25. Sasaki H., Okuda K., Kawano O., Endo K., Yukiue H., Yokoyama T., et al. Nras and Kras mutation in Japanese lung cancer patients: genotyping analysis using LightCycler. Oncol Rep 2007, 18:623-628.
26. Choi Y.H., Lee J.K., Kang H.J., Lee T.S., Kim H.R., Kim C.H., et al. Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer. J Thorac Oncol 2010, 5:1949-1952.
27. Jida M., Toyooka S., Mitsudomi T., Takano T., Matsuo K., Hotta K., et al. Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment. Cancer Sci 2009, 100:1931-1934.
28. Sakuma Y., Matsukuma S., Yoshihara M., Nakamura Y., Noda K., Nakayama H., et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol 2007, 128:100-108.
29. Nelson H.H., Christiani D.C., Mark E.J., Wiencke J.K., Wain J.C., Kelsey K.T. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999, 91:2032-2038.
30. Gealy R., Zhang L., Siegfried J.M., Luketich J.D., Keohavong P. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev 1999, 8:297-302.
31. De Gregorio L., Manenti G., Incarbone M., Pilotti S., Pastorino U., Pierotti M.A., et al. Prognostic value of loss of heterozygosity and KRAS2 mutations in lung adenocarcinoma. Int J Cancer 1998, 79:269-272.
32. Westra W.H., Slebos R.J., Offerhaus G.J., Goodman S.N., Evers S.G., Kensler T.W., et al. K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 1993, 72:432-438.
33. Keohavong P., Lan Q., Gao W.M., DeMarini D.M., Mass M.J., Li X.M., et al. K-ras mutations in lung carcinomas from nonsmoking women exposed to unvented coal smoke in China. Lung Cancer 2003, 41:21-27.
34. Hirsch F.R., Varella-Garcia M., Bunn P.A., Franklin W.A., Dziadziuszko R., Thatcher N., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:5034-5042.
35. Douillard J.Y., Shepherd F.A., Hirsh V., Mok T., Socinski M.A., Gervais R., et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28:744-752.
36. Sasaki T., Rodig S.J., Chirieac L.R., Janne P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010, 46:1773-1780.
37. Heinmoller P., Gross C., Beyser K., Schmidtgen C., Maass G., Pedrocchi M., et al. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res 2003, 9:5238-5243.
38. Yap T.A., Vidal L., Adam J., Stephens P., Spicer J., Shaw H., et al. Phase I, trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010, 28:3965-3972.